Her2-targeted pegylated liposomal doxorubicin: retention of target-specific binding and cytotoxicity after in vivo passage.
暂无分享,去创建一个
H. Shmeeda | D. Tzemach | L. Mak | A. Gabizon | Alberto Gabizon | Hilary Shmeeda | Lidia Mak | Dina Tzemach | Lidia Mak
[1] H. Shmeeda,et al. Pros and Cons of the Liposome Platform in Cancer Drug Targeting , 2006, Journal of liposome research.
[2] D. Slamon,et al. Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy. , 2000, Seminars in oncology.
[3] Ulrik B Nielsen,et al. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[4] V. Torchilin. Antibody-modified liposomes for cancer chemotherapy. , 2008, Expert Opinion on Drug Delivery.
[5] A. Schally. New Approaches to the Therapy of Various Tumors Based on Peptide Analogues , 2008, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
[6] Jianwei Zhu,et al. Preclinical Manufacture of an Anti‐HER2 scFv‐PEG‐DSPE, Liposome‐Inserting Conjugate. 1. Gram‐Scale Production and Purification , 2008, Biotechnology progress.
[7] Robert J. Lee,et al. Targeted drug delivery via folate receptors , 2008 .
[8] Y. Barenholz,et al. In vitro cytotoxicity of liposome-encapsulated doxorubicin: dependence on liposome composition and drug release. , 1992, Biochimica et biophysica acta.
[9] C. Wiele,et al. Receptor Imaging in Oncology by Means of Nuclear Medicine: Current Status , 2004 .
[10] A. Gabizon. Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. , 1992, Cancer research.
[11] Gustavo Helguera,et al. The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells. , 2006, Clinical immunology.
[12] Samuel Zalipsky,et al. Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates. , 2004, Advanced drug delivery reviews.
[13] C. Benz,et al. Future directions of liposome- and immunoliposome-based cancer therapeutics. , 2004, Seminars in oncology.
[14] Ulrik B Nielsen,et al. Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis. , 2002, Biochimica et biophysica acta.
[15] J. Baselga,et al. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] U. Nielsen,et al. Tumor targeting using anti-her2 immunoliposomes. , 2001, Journal of controlled release : official journal of the Controlled Release Society.
[17] John W. Park,et al. Preclinical Manufacture of Anti‐HER2 Liposome‐Inserting, scFv‐PEG‐Lipid Conjugate. 2. Conjugate Micelle Identity, Purity, Stability, and Potency Analysis , 2008, Biotechnology progress.
[18] D. Tzemach,et al. Dose Dependency of Pharmacokinetics and Therapeutic Efficacy of Pegylated Liposomal Doxorubicin (DOXIL) in Murine Models , 2002, Journal of drug targeting.
[19] U. Nielsen,et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. , 2006, Cancer research.
[20] Y. Yarden,et al. Targeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro and in vivo studies. , 1996, British Journal of Cancer.
[21] A. Gabizon,et al. Clinical pharmacology of liposomal anthracyclines: focus on pegylated liposomal Doxorubicin. , 2008, Clinical lymphoma & myeloma.
[22] Vladimir P Torchilin,et al. Tumor-targeted liposomes: doxorubicin-loaded long-circulating liposomes modified with anti-cancer antibody. , 2004, Journal of controlled release : official journal of the Controlled Release Society.
[23] T. Fleming,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.
[24] C. Shapiro,et al. Cardiac safety of liposomal anthracyclines. , 2004, Seminars in oncology.
[25] Samuel Zalipsky,et al. In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.